Product Images Losartan Potassium 25 Mg

This appears to be a table comparing the effectiveness of two medications, Atenolol and Sartan Potassium, in achieving a primary endpoint. The primary endpoint's impact percentage of both medications is not mentioned in the text. Further, adjusted risk reduction by 13% with p-value=0.021 is mentioned, which could be the efficacy difference between these two medications. Additionally, the table shows the study months from 6-66.*

This text shows a graph or a table with data related to the percentage of patients who had a fatal or non-fatal stroke. The data seems to be organized based on two groups of patients who were given different medications; one group was given Atenolol, and the other group was given Losartan potassium. The numbers on the top may represent the duration of the study in months. There isn't enough information available to draw any solid conclusions from this data.*

The text describes a study on the primary composite stroke rate (fatal and non-fatal) and the hazard ratio (with 95% CI) of patients taking Losartan Potassium and Atenolol Potassium. The results are shown for different age groups, genders, races, and medical conditions such as diabetes and history of CVD. Hazard ratios favoring Losartan Potassium are shown for some subgroups.*

The text provides information about risk reduction and p-value for an intervention along with a graph showing the percentage of patients with an event. The risk reduction is 16.1% and the p-value is 0.022. The graph has two bars showing 40% and 20% of patients with an event. It is unclear what type of event or population is being discussed.*

This is a label of Losartan Potassium 25mg tablets, relabeled by Proficient Rx LP. Each container has 90 tablets with the NDC 71205-675-90. The medicine is in the RX Only class and should be stored at 25°C (77°F) with Lot #:22010005. Vivimed Life Sciences Prvate Limited manufactured the tablets in India. The label warns to keep the medication out of the reach of children.*